MCL Literature Feed

This review summarizes current and emerging therapies for relapsed/refractory MCL, highlighting key strategies like BTKi/BCL2i combinations, CAR-T, and bispecific antibodies for this poor-prognosis population.

This review contextualizes CAR-T therapy's established role in relapsed/refractory MCL, summarizing universal challenges such as toxicity, access, cost, and the need for effective salvage treatments post-progression.

Experienced nurses and advanced practice providers outline key considerations for implementing a successful outpatient lisocabtagene maraleucel CAR-T program, offering a practical framework for managing MCL patients.

Real-world data show BTKi refractoriness and poor in-vivo brexu-cel expansion predict worse survival, identifying high-risk patients for early relapse and highlighting CAR-T kinetics as a key biomarker.

This review outlines management strategies for delayed complications of CAR T-cell therapy in MCL, moving beyond acute CRS and ICANS to improve long-term patient care and outcomes.

This case report details the management of severe brexu-cel toxicities, including a rare intestinal perforation, and highlights the use of anakinra for ICANS, emphasizing complex toxicity management.

This case report of late, recurrent neurotoxicity after brexucabtagene autoleucel demonstrates a mechanism of direct CNS infiltration by CAR-T cells, highlighting the need for long-term vigilance.

This first-in-literature case report identifies sclerosing cholangitis as a novel, severe hepatobiliary toxicity of Tecartus CAR-T therapy in a relapsed/refractory MCL patient, expanding the known safety profile.

This case report highlights the critical role of MRI in diagnosing post-CAR-T neurotoxicity in MCL, demonstrating findings like limbic encephalitis to differentiate ICANS from other CNS pathologies.

Italian experts established consensus diagnostic and therapeutic pathways for MCL, standardizing care while highlighting ongoing debates on MRD utility, immunotherapy sequencing, and CAR-T versus bispecifics.

This systematic review of brexu-cel for relapsed/refractory MCL reveals conflicting cost-effectiveness conclusions across different countries, highlighting major uncertainties for health systems considering its adoption and reimbursement.

This general review contextualizes CAR T-cell therapy, including its approved use in mantle cell lymphoma, within the broader landscape of cellular therapies, summarizing its efficacy and common toxicities.

This review outlines the clinical landscape and practical application of CAR-T and bispecific antibodies for relapsed/refractory MCL, guiding their integration into practice after targeted therapy failure.

This review summarizes the established efficacy and toxicities of CD19 CAR-T therapy in B-cell lymphomas, including MCL, while highlighting future research directions like novel targets and sequencing with bispecifics.

Real-world, intention-to-treat data from the French DESCAR-T registry confirms brexucabtagene autoleucel efficacy in relapsed/refractory MCL, providing practical outcomes for all patients intended for treatment.

This meta-analysis quantifies the poor prognosis (median OS ~9 months) for r/r MCL patients post-covalent BTKi treated with standard therapies, highlighting the superior efficacy of brexucabtagene autoleucel.

Bendamustine-induced lymphopenia in frontline MCL resolves by 12 months, suggesting a minimum 9-month wait before leukapheresis for CAR-T therapy to ensure sufficient lymphocyte collection.

This review synthesizes current data and practical considerations for CAR-T and bispecific antibodies, guiding clinical decision-making and sequencing for these T-cell engaging therapies in relapsed/refractory MCL.

This review explores CAR-NK cells as a promising alternative to CAR-T therapy for mantle cell lymphoma, potentially offering comparable efficacy with a significantly improved safety profile and fewer severe toxicities.

A meta-analysis of 7,604 patients found mantle cell lymphoma has the highest non-relapse mortality (10.6%) post-CAR-T, with infections being the primary cause, not CAR-T-specific toxicities.

This review synthesizes current and emerging therapies for relapsed/refractory MCL, including BTKi, BCL2i, CAR-T, and bispecifics, emphasizing the evolving challenge of post-BTKi treatment sequencing.

This review summarizes the evolving treatment landscape for relapsed/refractory MCL, highlighting survival gains from BTKi and CAR-T and outlining emerging therapies like bispecifics for multiply-refractory patients.

This case report details the practical challenges and potential toxicities of administering CAR-T cell therapy to an elderly MCL patient with high tumor burden, informing management of this high-risk group.

This meta-analysis of phase 2/3 trials quantifies venous thromboembolism risk after CAR-T therapy, providing crucial data to guide thromboprophylaxis strategies in MCL patients.

This multicenter real-world study demonstrates that CAR-T therapy can be an effective treatment for MCL patients with secondary CNS involvement, a population with historically poor outcomes.

CD20-targeted CAR-T therapy induced durable remissions (>7 years) in MCL by triggering a lasting endogenous anti-tumor immune response (epitope spreading) despite a lack of CAR-T persistence.

Bendamustine is a feasible alternative lymphodepletion for brexu-cel in MCL, showing comparable efficacy to standard cy/flu with less cytopenia, providing a critical option during drug shortages.

In a large real-world cohort, mantle cell lymphoma patients exhibited higher CAR19 expansion than other lymphomas, which directly correlated with increased toxicity and significantly higher steroid requirements.

The CDK9 inhibitor enitociclib overcomes resistance to both BTK inhibitors and CAR-T therapy, offering a potential new strategy for double-refractory mantle cell lymphoma.

This UK real-world, intention-to-treat analysis of brexu-cel confirms high efficacy in infused patients but reveals a 30% attrition rate before infusion and significant non-relapse mortality from infection.